AVI 7537

Drug Profile

AVI 7537

Alternative Names: AVI-7537

Latest Information Update: 01 Dec 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AVI BioPharma
  • Developer Sarepta Therapeutics
  • Class Antisense oligonucleotides; Antivirals
  • Mechanism of Action RNA interference; Viral RNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ebola virus infections
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Ebola virus infections

Most Recent Events

  • 11 Nov 2014 Phase-I clinical trials in Ebola virus infections (In volunteers) in USA (IV)
  • 23 Jan 2013 Sarepta Therapeutics terminates phase I trial (prior to enrolment for convenience of US government due to funding constraints) in Ebola virus infections (in volunteers) in USA (NCT01593072)
  • 07 Nov 2012 AVI 7537 receives Orphan Drug status for Ebola virus infections in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top